Skip to main content

Genome Therapeutics Sees Drop in Q4 Earnings and R&D Spending, Net Losses Widen

NEW YORK, March 4 - Genome Therapeutics reported today a fall-off in revenues for the fourth quarter ended December 31, 2002, along with lower R&D spending and a slightly increased net loss.


The company posted revenues of $5.8 million for the quarter, down from $8.9 million in the fourth quarter of 2001.


Research and development expenses for the quarter fell to $7.1 million, compared to $10.5 million in the same period of 2001. For the year, the company's R&D spending increased to $32 million from $24 million in the prior year. Genome Therapeutics attributed this increase to clinical development of its Phase III anti-infective candidate, Ramoplanin, as well as increased investment in internal research programs in anti-infectives and chronic human diseases. Total expenses for the quarter were down, at $14.5 million compared to $17.3 million for the fourth quarter of 2001.


The company's net loss widened to $8.8 million for the quarter, or $0.38 per basic and diluted share, compared to a net loss of $7.9 million, or $0.35 per basic and diluted share for the same period of 2001.


Genome Therapeutics had $51 million in cash, cash equivalents, restricted cash, and marketable securities at the end of 2002, compared to $67 million at the end of 2001. The company's current cash holdings include $15 million raised through a convertible financing last year. 


For the fiscal year ending December 31, 2003, Genome Therapeutics said it expects a net loss of $20 million to $25 million.


Click here for further information.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.